Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models

Hepatology

Volumn 57, Issue 5, 2013, Pages 1793-1805

  Coulon, Stephanie ^a   Legry, Vanessa ^b   Heindryckx, Femke ^a   Van Steenkiste, Christophe ^a   Casteleyn, Christophe ^c   Olievier, Kim ^a   Libbrecht, Louis ^a   Carmeliet, Peter ^d   Jonckx, Bart ^e   Stassen, Jean Marie ^e   Van Vlierberghe, Hans ^a   Leclercq, Isabelle ^b   Colle, Isabelle ^a   Geerts, Anja ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e ThromboGenics NV   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 1; PLACENTAL GROWTH FACTOR; RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEPATITIS; LIVER CIRCULATION; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELLS, CULTURED; CHOLINE DEFICIENCY; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FATTY LIVER; FEMALE; HEPATOCYTES; LIPID METABOLISM; LIVER; METHIONINE; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, MUTANT STRAINS; NEOVASCULARIZATION, PATHOLOGIC; PREGNANCY PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84876704640     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26219     Document Type: Article

References (35)

1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharm Ther 2011; 34: 274-285.
2. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Cllin Gastroenterol 2006; 40( Suppl 1): S17-S29.
3. Lam BP, Younossi ZM. Treatment regimens for non-alcoholic fatty liver disease. Ann Hepatol 2009; 8( Suppl 1): S51-S59.
4. James OF, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998; 29: 495-501.
5. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. HEPATOLOGY 2010; 52: 1836-1846.
6. Medina J, Arroyo AG, Sánchez-Madrid F, Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. HEPATOLOGY 2004; 39: 1185-95.
7. Fernández M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 2009; 50: 604-620.
8. Heindryckx F, Mertens K, Charette N, Vandeghinste B, Casteleyn C, Van Steenkiste C, et al. Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma. Mol Cancer 2010; 9: 219.
9. Geerts AM, De Vriese AS, Vanheule E, Van Vlierberghe H, Mortier S, Cheung KJ, et al. Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vivo study. Liver Int 2006; 26: 889-898.
10. Steenkiste CV, Ribera J, Geerts A, Pauta M, Tugues S, Casteleyn C, et al. Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. HEPATOLOGY 2011; 53: 1629-1640.
11. Kitade M, Yoshiji H, Kojima H, Ikenaka Y, Noguchi R, Kaji K, et al. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. HEPATOLOGY 2006; 44: 983-991.
12. Cayon A, Crespo J, Guerra AR, Pons-Romero F. Gene expression in obese patients with non-alcoholic steatohepatitis. Rev Esp Enferm Dig 2008; 100: 212-218.
13. Kitade M, Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Shirai Y, et al. Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis. World J Gastroenterol 2009; 15: 5193-5199.
14. Tarantino G, Conca P, Pasanisi F, Ariello M, Mastrolia M, Arena A, et al. Could inflammatory markers help diagnose nonalcoholic steatohepatitis? Eur J Gastroenterol Hepatol 2009; 21: 504-511.
15. Coulon S, Francque S, Colle I, Verrijken A, Blomm B, Heindryckx F, et al. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine 2012; 59: 442-449.
16. Rinella M, Elias M, Smolak R, Fu T, Borensztain J, Green R. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res 2008; 49: 1068-1076.
17. Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P, et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 1998; 17: 155-161.
18. Luttun A, Tjwa M, Carmeliet P. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann N Y Acad Sci 2002; 979: 80-93.
19. Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16: 5286-5296.
20. Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. HEPATOLOGY 2009; 49: 1132-1140.
21. Cousin S, Hügl S, Wrede C, Kajio H, Meyers M, Rhodes C. Free fatty acid-induced inhibition of glucose and insulin-like growth factor I-induced deoxyribonucleic acid synthesis in the pancreatic beta-cell line INS-1. Endocrinology 2001; 142: 229-240.
22. Kitade M. Neovascularization and oxidative stress in the progression of non-alcoholic steatohepatitis. Mol Med Rep 2008; 1: 543.
23. Noguchi R, Yoshiji H, Ikenaka Y, Kaji K, Shirai Y, Aihara Y, et al. Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats. Int J Mol Med 2010; 26: 407.
24. Kumar P, Wang JM, Bernabeu C. CD 105 and angiogenesis. J Pathol 1996; 178: 363-366.
25. Tjwa M, Luttun A, Autiero M, Carmeliet P. VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis. Cell Tissue Res 2003; 314: 5-14.
26. McCuskey RS, Ito Y, Robertson GR, McCuskey MK, Perry M, Farrell GC. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. HEPATOLOGY 2004; 40: 386-393.
27. Salcedo X, Medina J, Sanz-Cameno P, García-Buey L, Martín-Vilchez S, Moreno-Otero R. Review article: angiogenesis soluble factors as liver disease markers. Aliment Pharmacol Ther 2005; 22: 23-30.
28. Van Steenkiste C, Trachet B, Casteleyn C, van Loo D, Van Hoorebeke L, Segers P, et al. Vascular corrosion casting: analyzing wall shear stress in the portal vein and vascular abnormalities in portal hypertensive and cirrhotic rodents. Lab Invest 2010; 90: 1558-1572.
29. Taura K, De Minicis S, Seki E, Hatano E, Iwaisako K, Osterreicher C, et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology 2008; 135: 1729-1738.
30. Chaparro M, Sanz-Cameno P, Trapero-Marugan M, Garcia-Buey L, Moreno-Otero R. Mechanisms of angiogenesis in chronic inflammatory liver disease. Ann Hepatol 2010; 6: 208-13.
31. Tam J, Duda DG, Perentes JY, Quadri RS, Fukumura D, Jain RK. Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cells. PloS One 2009; 4: 4974.
32. Imhof BA, Aurrand-Lions M. Angiogenesis and inflammation face off. Nat Med 2006; 12: 171-172.
33. Li ZZ, Berk M, McIntyre TM, Feldstein AE. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem 2009; 284: 5637-5644.
34. Rizki G, Arnaboldi L, Gabrielli B, Yan J, Lee GS, Ng RK, et al. Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1. J Lipid Res 2006; 47: 2280-2290.
35. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007; 47: 571-579.